RxDoctor Payments Data

Nathan Overbey, MD

Interventional Pain Medicine · Oklahoma City, OKNPI 1457795247

Payments from drug & device makers

What this record shows

This record is dominated by food and beverage: $3,295 of the $5,328 with a category attached, or 61.9%. Medtronic accounts for 68.5% of it on its own, with 30 other manufacturers making up the rest. Reporting peaked in 2022 at $1,712 and has fallen 88.1% since, to $204 in 2025.

$5,328in general payments, 2019–2025

Across 166 payments — averaging $32.09 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Medtronic$4K
  • Tersera Therapeutics LLC$216
  • Pfizer$207
  • Amgen$173
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$147
  • Boston Scientific$90
  • plus $844 from 25 others

What the payments were for

  • Travel & lodging$2,03238%
  • Food & beverage$3,29562%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$5,328 in reported general payments places this provider in the 60th percentile of 27 interventional pain medicine providers in Oklahoma.

See all interventional pain medicine providers in Oklahoma

Medicare billing

Part B allowed, 2024
$166,892
Medicare patients
506
Services billed
1,825

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Pregabalin53$1,194
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen44$556
Gabapentin31$403
Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen24$282
Duloxetine Hcl12$138
Tizanidine Hcl17$124

Paid to pharmacies, not to this prescriber.

Other interventional pain medicine in Oklahoma City

See the full list for Oklahoma

Where these figures come from

Is this you, or does something look wrong? →